OPTINOSE INC (OPTN)
US68404V1008 - Common Stock
Overall OPTN gets a fundamental rating of 2 out of 10. We evaluated OPTN against 192 industry peers in the Pharmaceuticals industry. OPTN may be in some trouble as it scores bad on both profitability and health. OPTN shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
OPTN had negative earnings in the past year.
OPTN had a negative operating cash flow in the past year.
OPTN had negative earnings in each of the past 5 years.
OPTN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
OPTN has a Return On Assets (-34.51%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.51% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-44.79%
ROA(5y)-50.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 90.46%, OPTN belongs to the top of the industry, outperforming 93.48% of the companies in the same industry.
OPTN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for OPTN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y2.53%
2. Health
2.1 Basic Checks
OPTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPTN has more shares outstanding
The number of shares outstanding for OPTN has been increased compared to 5 years ago.
OPTN has a worse debt/assets ratio than last year.
2.2 Solvency
OPTN has an Altman-Z score of -5.01. This is a bad value and indicates that OPTN is not financially healthy and even has some risk of bankruptcy.
OPTN's Altman-Z score of -5.01 is on the low side compared to the rest of the industry. OPTN is outperformed by 64.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.01 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
OPTN has a Current Ratio of 0.79. This is a bad value and indicates that OPTN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.79, OPTN is not doing good in the industry: 92.39% of the companies in the same industry are doing better.
OPTN has a Quick Ratio of 0.79. This is a bad value and indicates that OPTN is not financially healthy enough and could expect problems in meeting its short term obligations.
OPTN has a Quick ratio of 0.72. This is amonst the worse of the industry: OPTN underperforms 89.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
OPTN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.00%, which is quite impressive.
Looking at the last year, OPTN shows a very strong growth in Revenue. The Revenue has grown by 25.80%.
OPTN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 58.62% yearly.
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)25.8%
Revenue growth 3Y13.06%
Revenue growth 5Y58.62%
Sales Q2Q%3.1%
3.2 Future
Based on estimates for the next years, OPTN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.52% on average per year.
OPTN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.04% yearly.
EPS Next Y33.86%
EPS Next 2Y30.89%
EPS Next 3Y30.51%
EPS Next 5Y25.52%
Revenue Next Year12.22%
Revenue Next 2Y31.03%
Revenue Next 3Y29.9%
Revenue Next 5Y33.04%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OPTN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPTN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OPTN's earnings are expected to grow with 30.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.89%
EPS Next 3Y30.51%
5. Dividend
5.1 Amount
No dividends for OPTN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OPTINOSE INC
NASDAQ:OPTN (1/6/2025, 8:00:02 PM)
After market: 5.82 -0.3 (-4.9%)6.12
-0.38 (-5.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.94%
Inst Owner Change0%
Ins Owners5.9%
Ins Owner Change-0.44%
Market Cap923.08M
Analysts84
Price TargetN/A
Short Float %2.25%
Short Ratio3.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.27%
Min EPS beat(2)36.54%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)33.39%
Min EPS beat(4)-9.44%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)31.69%
EPS beat(12)9
Avg EPS beat(12)22.07%
EPS beat(16)12
Avg EPS beat(16)17.79%
Revenue beat(2)0
Avg Revenue beat(2)-7.65%
Min Revenue beat(2)-12.9%
Max Revenue beat(2)-2.4%
Revenue beat(4)2
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-12.9%
Max Revenue beat(4)8.75%
Revenue beat(8)5
Avg Revenue beat(8)3.03%
Revenue beat(12)6
Avg Revenue beat(12)-0.49%
Revenue beat(16)8
Avg Revenue beat(16)-1.06%
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-216.67%
EPS NY rev (1m)0%
EPS NY rev (3m)8.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-30.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.6
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.51% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.46% | ||
| FCFM | N/A |
ROA(3y)-44.79%
ROA(5y)-50.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y2.53%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.18% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | -5.01 |
F-Score5
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)39.69%
Cap/Depr(5y)41.44%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y33.86%
EPS Next 2Y30.89%
EPS Next 3Y30.51%
EPS Next 5Y25.52%
Revenue 1Y (TTM)25.8%
Revenue growth 3Y13.06%
Revenue growth 5Y58.62%
Sales Q2Q%3.1%
Revenue Next Year12.22%
Revenue Next 2Y31.03%
Revenue Next 3Y29.9%
Revenue Next 5Y33.04%
EBIT growth 1Y4.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.84%
EBIT Next 3Y38.42%
EBIT Next 5YN/A
FCF growth 1Y40.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.55%
OCF growth 3YN/A
OCF growth 5YN/A